Scholarlink

<p>Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetrical parkinsonism, dystonia, myoclonus) and cortical impairments (apraxia, disturbances of complex types of sensation, alien limb phenomenon). CBS is most commonly based on the pathology of corticobasal degeneration (CBD) or Alzheimer’s disease (AD). Differentiating between these diseases solely on the basis of clinical and neuroimaging data is in some cases difficult. The use of biomarkers for AD may be crucial for establishing an accurate diagnosis. Observations of two patients with CBS and Alzheimer-type memory disorders are presented here. Brain MRI revealed asymmetrical cortical atrophy. These patients showed significantly decreased Aβ42 levels in the cerebrospinal fluid, giving diagnoses of AD. Issues of the differential diagnosis of CBD- and AD-associated CBS are discussed. The use of biomarkers in atypical clinical presentations of AD may allow diagnoses to be made at early stages of disease. Accurate diagnosis of AD is necessary both for the prompt prescription of available symptomatic drugs and for identifying indications for pathogenetic anti-amyloid therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosis of Alzheimer’s Disease Using Biological Markers in Corticobasal Syndrome

  • 期刊论文

  • 发表日期：

    2026年1月26日

查看全文
  • D. A. Grishina,
  • V. V. Grinyuk,
  • M. R. Nodel,
  • A. Yu. Tyurina,
  • E. A. Mkhitaryan,
  • Ya. I. Chervyakova

摘要

Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetrical parkinsonism, dystonia, myoclonus) and cortical impairments (apraxia, disturbances of complex types of sensation, alien limb phenomenon). CBS is most commonly based on the pathology of corticobasal degeneration (CBD) or Alzheimer’s disease (AD). Differentiating between these diseases solely on the basis of clinical and neuroimaging data is in some cases difficult. The use of biomarkers for AD may be crucial for establishing an accurate diagnosis. Observations of two patients with CBS and Alzheimer-type memory disorders are presented here. Brain MRI revealed asymmetrical cortical atrophy. These patients showed significantly decreased Aβ42 levels in the cerebrospinal fluid, giving diagnoses of AD. Issues of the differential diagnosis of CBD- and AD-associated CBS are discussed. The use of biomarkers in atypical clinical presentations of AD may allow diagnoses to be made at early stages of disease. Accurate diagnosis of AD is necessary both for the prompt prescription of available symptomatic drugs and for identifying indications for pathogenetic anti-amyloid therapy.